Last $3.92 USD
Change Today +0.03 / 0.77%
Volume 16.5K
RESX On Other Exchanges
Symbol
Exchange
OTC US
As of 3:36 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Open
$3.90
Previous Close
$3.89
Day High
$4.00
Day Low
$3.90
52 Week High
07/25/13 - $19.00
52 Week Low
03/5/14 - $2.37
Market Cap
58.3M
Average Volume 10 Days
3.3K
EPS TTM
$1.57
Shares Outstanding
14.9M
EX-Date
--
P/E TM
2.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for dermatology, ophthalmology, and women’s health. Its product under development includes HYG-102, a soft estrogen for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen for the treatment of androgen excess, e.g. acne, male-pattern baldness, and hirsutism; and P529, a prescription dermatology compound used for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren’s disease, and the bullous blistering diseases. RestorGenex Corporation has Collaboration Agreement with Ferndale Pharma Group, Inc. for developing aging skin product. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is based in Los Angeles, California.

restorgenex corp (RESX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

restorgenex corp (RESX) Key Developments

Restorgenex Corporation Announces Management Changes

Restorgenex Corporation announced several management changes. The company has appointed Phillip B. Donenberg as its chief financial offer. Before RestorGenex, he served as BioSante Pharmaceuticals Inc.'s Senior Vice President of Finance from 2010 until June 19, 2013 and Chief Financial Officer and Secretary from 1998 until June 19, 2013 when BioSante merged with ANIP Acquisition Company, d/b/a ANI Pharmaceuticals Inc. In other developments, it has appointed Yael Schwartz, PhD as its Executive Vice President of Preclinical Development. Previously, Dr. Schwartz was president of RestorGenex's Canterbury/Hygeia wholly owned subsidiaries. In addition, the company announced that David Sherris, Ph.D.'s new title is Chief Scientific Officer of RestorGenex. Previously, Dr. Sherris was Chief Scientific Officer and President of RestorGenex's Paloma/VasculoMedics wholly owned subsidiaries. Jerold Rubinstein, former CEO and chair of the audit committee, resigned from the RestorGenex board of directors as part of the company's efforts to achieve a majority of independent directors in anticipation of an application to list the company's common stock on the NASDAQ Stock Market. Mr. Rubinstein will remain a senior advisor to the RestorGenex board of directors for at least the year 2015.

Restorgenex Corporation Announces Executive Changes

Restorgenex Corporation announced that the company has appointed Phillip B. Donenberg as Chief Financial Officer. Mr. Donenberg replaces John F. Moynahan who resigned as Chief Financial Officer effective with Mr. Donenberg's appointment. Mr. Moynahan has transitioned into a consulting role with the company and it is anticipated that the company and Mr. Moynahan will enter into a separation and release agreement. Mr. Donenberg, age 53, served as BioSante Pharmaceuticals Inc.'s Senior Vice President of Finance from 2010 until June 19, 2013 and Chief Financial Officer and Secretary from 1998 until June 19, 2013.

Restorgenex Corporation announced delayed 10-Q filing

On 05/15/2014, Restorgenex Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $3.92 USD +0.03

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies
 

Industry Analysis

RESX

Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 322.9x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 952.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit www.stratusmediagroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.